Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | UBE2M | P61081 | 9/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 9/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL843357 | 0.99 | GALR3 (0.39) | GALR3RAB9AMCHR1TP53UBE2M | |
| SCHEMBL1983490 | 0.99 | GALR3 (0.40) | GALR3RAB9AMCHR1TP53UBE2M | |
| Hydrochloric Acid SCHEMBL841545 | 0.98 | GALR3 (0.39) | GALR3RAB9AMCHR1TP53UBE2M | |
| SCHEMBL1983526 | 0.95 | GALR3 (0.40) | GALR3RAB9AMCHR1TP53UBE2M | |
| SCHEMBL841947 | 0.95 | GALR3 (0.39) | GALR3RAB9AMCHR1TP53UBE2M | |
| Hydrochloric Acid SCHEMBL843046 | 0.95 | GALR3 (0.39) | GALR3RAB9AMCHR1TP53UBE2M | |
| Hydrochloric Acid SCHEMBL842916 | 0.94 | GALR3 (0.38) | GALR3RAB9AMCHR1TP53UBE2M | |
| SCHEMBL1983613 | 0.93 | GALR3 (0.39) | GALR3RAB9AMCHR1TP53UBE2M | |
| SCHEMBL1980383 | 0.93 | MCHR1 (0.41) | GALR3RAB9AMCHR1TP53UBE2M | |
| SCHEMBL1981620 | 0.93 | GALR3 (0.44) | GALR3RAB9AMCHR1UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410276-B2 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-02 | — | — | US | claimed |
| EP-2546234-A1 | Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-01-16 | — | — | EP | claimed |
| US-20110152520-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152520-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CXCR3, CCR5, CCR1 | GALR3 650/4885RAB9A 953/4885MCHR1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.